Charles Schwab Investment Management Inc. Acquires 18,874 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Charles Schwab Investment Management Inc. raised its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 3.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 586,063 shares of the medical device company's stock after acquiring an additional 18,874 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.89% of Tandem Diabetes Care worth $24,855,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TNDM. Assetmark Inc. bought a new stake in Tandem Diabetes Care in the 3rd quarter valued at $29,000. ORG Wealth Partners LLC acquired a new stake in Tandem Diabetes Care during the third quarter worth about $30,000. ORG Partners LLC acquired a new position in Tandem Diabetes Care during the second quarter valued at approximately $31,000. Waldron Private Wealth LLC acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter worth $50,000. Finally, Headlands Technologies LLC boosted its stake in shares of Tandem Diabetes Care by 110.0% in the 2nd quarter. Headlands Technologies LLC now owns 2,060 shares of the medical device company's stock valued at $83,000 after purchasing an additional 1,079 shares in the last quarter.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the firm's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the director now directly owns 195,190 shares of the company's stock, valued at $5,855,700. This trade represents a 4.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TNDM. Royal Bank of Canada began coverage on shares of Tandem Diabetes Care in a report on Wednesday, October 2nd. They issued an "outperform" rating and a $65.00 price objective for the company. Robert W. Baird cut their target price on Tandem Diabetes Care from $39.00 to $37.00 and set a "neutral" rating on the stock in a research report on Thursday, November 7th. The Goldman Sachs Group started coverage on Tandem Diabetes Care in a research note on Friday, October 4th. They set a "neutral" rating and a $46.00 target price for the company. Barclays raised their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an "overweight" rating in a report on Friday, November 8th. Finally, Sanford C. Bernstein assumed coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They set an "outperform" rating and a $42.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.25.

Tandem Diabetes Care Stock Down 0.5 %

Shares of NASDAQ TNDM traded down $0.16 during trading on Friday, hitting $30.11. The stock had a trading volume of 923,119 shares, compared to its average volume of 1,586,094. The firm has a fifty day moving average of $33.85 and a two-hundred day moving average of $40.41. The company has a market capitalization of $1.98 billion, a PE ratio of -15.52 and a beta of 1.32. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care, Inc. has a 12 month low of $21.85 and a 12 month high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The business had revenue of $243.97 million during the quarter, compared to the consensus estimate of $224.14 million. During the same period in the prior year, the firm posted ($0.38) EPS. The firm's quarterly revenue was up 31.4% compared to the same quarter last year. As a group, equities research analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.